NCT04105543View on ClinicalTrials.gov

CLR 131 Combined With Radiation for Head and Neck Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 20, 2019

Primary Completion Date

September 19, 2022

Study Completion Date

February 1, 2024

Conditions
Head and Neck Cancer
Interventions
DRUG

CLR 131

CLR 131 is a radiopharmaceutical dosed intravenously over a period of approximately 30 minutes, dose will be based on total body surface area calculated from actual body weight and height

Trial Locations (2)

53038

UW Cancer Center Johnson Creek, Johnson Creek

53792

University of Wisconsin Carbone Cancer Center, Madison

Sponsors
All Listed Sponsors
collaborator

National Institute of Dental and Craniofacial Research (NIDCR)

NIH

collaborator

Cellectar Biosciences, Inc.

INDUSTRY

lead

University of Wisconsin, Madison

OTHER